Therapeutic targeting of PPFIA1 and PARP1 in the miR-181a/PPFIA1/PARP1/NF-κB-P65/KIT axis can control the expression of KIT in CML. This evidence concerns the gene PPFIA1 and chronic myelogenous leukemia, BCR-ABL1 positive.